 |
|
Antibiotics and Coronary Heart Disease—Reply
|
|
| Since this article does not have an abstract, we have provided the first 142 words of the full text and any section headings. |
|
|
|
In Reply: We agree with Drs Modest and Kaufmann that CRP might be helpful in identifying patients most likely to respond to antibiotic treatment. We are currently exploring the importance of CRP, other markers of inflammation, and additional measures of C pneumoniae infection as part of our trial.
Dr Nieto cites data to support the role of C pneumoniae in both the initiation of an atherosclerotic plaque and the progression of such plaques. We agree that a secondary prevention trial cannot define the value of an intervention in a primary prevention setting. We chose a secondary prevention trial to study the use of azithromycin mainly for logistical reasons centered on the incidence of cardiovascular events and the potentially more favorable risk-benefit assessment were the outcome to be successful.
Please refer to the original article for author affiliations and financial disclosures.—ED.
Michael W. Dunne, MD;
Rebecca J. Benner, PhD;
Christopher M. O'Connor, MD;
Marc A. Pfeffer, MD, PhD;
Joseph B. Muhlestein, MD;
Louis Yao, MD;
Sandeep Gupta;
Marian R. Fisher, PhD;
Thomas D. Cook, PhD
Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.
JAMA. 2004;291:303.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Azithromycin for the Secondary Prevention of Coronary Heart Disease Events: The WIZARD Study: A Randomized Controlled Trial
, , , , , , , , and
JAMA. ;290():1459-1466.
FULL TEXT
Antibiotics and Coronary Heart Disease
and
JAMA. ;291():302-302.
FULL TEXT
Antibiotics and Coronary Heart Disease
JAMA. ;291
():302-303.
FULL TEXT
Antibiotics and Coronary Heart Disease--Reply
and
JAMA. ;291
():303-303.
FULL TEXT
|
